Close

EDAP TMS S.A. (EDAP) Announces Prelim. Q4 Revenue of EUR10.7M

February 23, 2017 7:39 AM EST

EDAP Announces Preliminary Unaudited Full Year 2016 Revenue

  • Full year 2016 revenue increased to approximately €35.6 million
  • 2016 HIFU revenues recorded over 63% growth
  • Strong cash position of €22 million
  • Company to announce fourth quarter and full year 2016 results April 3rd with accompanying conference call April 4th

EDAP TMS SA (NASDAQ: EDAP), the global leader in therapeutic ultrasound, announced today that its unaudited Fourth Quarter 2016 revenue is estimated to be €10.7 million and its full year 2016 revenues to be around €35.6 million, an increase of 10% as compared to revenue of €32.3 million for the full year 2015.

The Company estimates that as of December 31, 2016, it had €22 million of cash on hand.

Marc Oczachowski, Chief Executive Officer, commented: "We are pleased with our 2016 revenue and EDAP's continued growth, mainly driven by 63% growth in our HIFU division. With €22 million of cash on hand at the end of the year, we are well positioned to pursue our development programs and marketing expansion strategy to make our innovative HIFU technology available worldwide."

The Company also announced that it will report fourth quarter and full year 2016 results after the close of the market on Monday, April 3rd, 2017. An accompanying conference call will be hosted by Marc Oczachowski, CEO and Francois Dietsch, Chief Financial Officer at 8:30 AM ET on Tuesday, April 4th, 2017. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Details

Conference Date: Tuesday, April 4th, 2017 8:30 AM ET

Conference dial-in: 877-269-7756

International dial-in: 201-689-7817

Conference Call Name: EDAP-TMS Fourth Quarter and Full Year 2016 Results Call

Webcast Registration: Click Here

Following the live call, a replay will be available on the Company's website, www.edap-tms.com under "Investors Information."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Guidance

Related Entities

FDA